Complications of antitumor treatment of rectal cancer: structural features and prerequisites for development
https://doi.org/10.33878/2073-7556-2025-24-2-112-120
Abstract
AIM: to find structural features and prerequisites for the development of complications of antitumor treatment of rectal cancer.
PATIENTS AND METHODS: for the analysis, a cohort of 302 patients was formed who were treated in 2017–2018. The inclusion criterion was verified rectal cancer. The study was retrospective, the primary endpoint was the complication rate of antitumor treatment. The distribution of patients by gender was almost equal: 148/302 (49.0%) women and 154/302 (51.0%) men. The age of patients ranged from 31 to 86 (65.2 ± 9.9) years. All 100% of patients underwent surgery for a rectal tumor. In 145 (48.0%) patients, treatment was limited to a surgical aid, in 28 (9.3%) — was supplemented with radiation therapy, in 86 (28.5%) — chemotherapy, in 43 (14.2%) a combination of all three treatment methods was used.
RESULTS: complications of antitumor treatment occurred in 118 (39.1%) patients. The vast majority of them — 95 (31.5%) cases — were postoperative. About half of them were associated with wound healing — 47 (15.5%). The most significant predictors of complications were the tumour differentiation (Area under the curve (AUC) = 0.58; 95% confidence interval (CI): 0.52–0.64; р = 0.007) and the tumour distance from the distal margin to the dentate line (AUC = 0.63; 95% CI: 0.53–0.64; p = 0.0009). In the structure of comorbidity, a significantly high probability of treatment complications was detected in patients with diabetes mellitus (RR = 4.05; 95% CI: 3.16–5.20; p < 0.0001), obesity (RR = 3.11; 95% CI: 2.52–3.83; p < 0.0001), varicose veins of the lower extremities (RR = 1.81; 95% CI: 1.36–2.41; p < 0.0001).
CONCLUSION: the available statistically confirmed data on the prognostic potential of each analyzed indicator can be used in the future to compile an algorithm for the formation of risk groups even before the start of antitumor treatment of rectal cancer.
About the Author
M. M. Ryabov
Yaroslavl State Medical University
Russian Federation
Russian Federation
Mikhail M. Ryabov
Revolyutsionnaya st., 5, Yaroslavl, 150000
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Canc J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
2. Krashenkov O.P., Kostin A.A., Konovalov O.E. Gender-specific incidence of colorectal cancer. Collection of materials of the conference “Topical issues of preventive medicine and sanitary and epidemiological well-being of the population: factors, technologies, management and risk assessment.” 2022; 470-473. (In Russ.).
3. Dubovichenko D.M., Valkov M.Y., Merabishvili V.M., et al. Rectal cancer incidence and mortality (literature review and own study). Oncology issues. 2019;65(6):816–824. (In Russ.). doi: 10.37469/0507-3758-2019-65-6-816-824
4. Kostin A.A., Ryabov M.M., Konovalov O.E., et al. Complications of surgical treatment of rectal cancer as a clinical-organizational and medical-social problem (literature review). VSKM. 2024;17(3):59–66. (In Russ.). doi: 10.20969/VSKM.2024.17(3).59-66
5. Lukmonov S.M., Belenkaya Y.V., Lebedko M.S., et al. Effect of preoperative treatment on the incidence of postoperative complications in upper ampullary rectal cancer. Pelvic surgery and oncology. 2023;13(2):46–53. (In Russ.). doi: 10.17650/2686-9594-2023-13-2-46-53
6. Styazhkina S.N., Kutbedinov H.S., Andrianov A.I., et al. Complications of rectal cancer in combination with liver metastasis. Modern Science. 2022;1(2):193–195. (In Russ.).
7. Larichev A.B., Ryabov M.M., Smirnova A.V., et al. Perioperative antibiotic prophylaxis: the pathogenetic realities of breast surgery. Medical Bulletin of Bashkortostan. 2023;17(4):18–22. (In Russ.).
8. Malysheva Y.V., Petrochenko E.P., Tikhomirova I.A., et al. Hemostatic potential in patients with postoperative colorectal cancer. Hematology and transfusiology. 2016; 16(1, Suppl. 1): 146. (In Russ.).
9. Montroni I, Di Candido F, Taffurelli G, et al. Total neoadjuvant therapy followed by total mesorectal excision for rectal cancer in older patients real world data and proof of concept. Front Surg. 2024 Nov 19;11:1448073. doi: 10.3389/fsurg.2024.1448073
10. Brière R, Simard AJ, Rouleau-Fournier F, et al. Perioperative management and survival outcomes following cytoreductive surgery in patients with peritoneal metastases from rectal cancer: A scoping review. Eur J Surg Oncol. 2024 Nov 24;51(2):109498. doi: 10.1016/j.ejso.2024.109498
11. Calu V, Piriianu C, Miron A, et al. Utilizing C-Reactive Protein (CRP) and CRP Ratios for Early Detection of Postoperative Complications Following Rectal Cancer Surgery. Life (Basel). 2024 Nov 12;14(11):1465. doi: 10.3390/life14111465
Review
For citations:
Ryabov M.M. Complications of antitumor treatment of rectal cancer: structural features and prerequisites for development. Koloproktologia. 2025;24(2):112-120. https://doi.org/10.33878/2073-7556-2025-24-2-112-120
Views:
264
Email this article 
